In the fourth quarter, Altria reported modest adjusted diluted EPS growth of approximately 3%, driven by an average industry price increase of 5% that offset a 2% decline in cigarette volume. Marlboro brand volumes declined 1.8% year-over-year but held a strong 39.5% share of the US combustible market, underscoring Altria’s continued pricing power. Total revenue rose by 1.5% to $5.8 billion, reflecting resilience in the smokeable segment, which still accounts for nearly 88% of company sales. Cash flow from operations increased by 4% to $3.2 billion, bolstered by disciplined working capital management.

Altria maintained a quarterly dividend that translates to a nearly 7% yield, supported by a free cash flow payout ratio of around 75%. During Q4, the company repurchased $650 million of common shares, bringing year-to-date buybacks to $2.4 billion and demonstrating a commitment to shareholder returns. Net leverage stood at a manageable 3.1x EBITDA at year-end, in line with management’s target range, ensuring capacity to sustain distributions through cyclical soft patches. Credit rating agencies continue to view Altria’s balance sheet favorably, with stable outlooks reinforcing dividend safety.

Altria’s smoke-free product initiatives gained traction in Q4, with oral nicotine pouch revenue up 12% sequentially following the December FDA marketing order for the company’s on!® brand. While smoke-free still represents less than 5% of total revenue, management projects mid-single-digit unit growth in 2026 as distribution expands into 40,000 US outlets. The acquisition of a European vapour business in November is expected to add scale and accelerate technological development. Research and development investments reached $150 million in 2025, supporting next-generation product launches and reinforcing long-term strategic positioning.